SHARLA-LOUISE TOVER: Open Payments
NPI 1992401400 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,120 in 50 payments from 14 companies in 2025. Trend: 2023 $271 · 2024 $1,286 · 2025 $1,120
Food & beverage: $1,120
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $338 |
| Vanda Pharmaceuticals Inc. | 8 | $148 |
| E.R. Squibb & Sons, L.L.C. | 4 | $103 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $83 |
| Teva Pharmaceuticals USA, Inc. | 2 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Tris Pharma Inc | 3 | $63 |
| Neurocrine BioSciences, Inc. | 2 | $55 |
| Almatica Pharma LLC | 1 | $29 |
Products named: VRAYLAR, COBENFY, FANAPT, CAPLYTA, TRINTELLIX, AUSTEDO XR, Dyanavel XR, INGREZZA.
Industry payments across NV — which companies pay providers there.
